Charles Schwab Investment Management Inc. Has $10.98 Million Stock Holdings in Novavax, Inc. (NASDAQ:NVAX)

Charles Schwab Investment Management Inc. lifted its position in Novavax, Inc. (NASDAQ:NVAX) by 3.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,365,414 shares of the biopharmaceutical company’s stock after buying an additional 39,906 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Novavax were worth $10,978,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of NVAX. Spire Wealth Management bought a new stake in shares of Novavax in the 4th quarter worth about $29,000. KBC Group NV lifted its position in Novavax by 97.0% during the 4th quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company’s stock valued at $64,000 after purchasing an additional 3,917 shares during the period. TigerOak Management L.L.C. acquired a new stake in shares of Novavax in the 4th quarter valued at approximately $86,000. Beirne Wealth Consulting Services LLC raised its position in shares of Novavax by 65.0% in the 4th quarter. Beirne Wealth Consulting Services LLC now owns 16,500 shares of the biopharmaceutical company’s stock valued at $133,000 after acquiring an additional 6,500 shares during the period. Finally, Victory Capital Management Inc. raised its position in shares of Novavax by 12.0% in the 3rd quarter. Victory Capital Management Inc. now owns 19,292 shares of the biopharmaceutical company’s stock valued at $244,000 after acquiring an additional 2,072 shares during the period. 53.04% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Novavax

In related news, Director James F. Young sold 5,400 shares of the stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $8.00, for a total transaction of $43,200.00. Following the completion of the sale, the director now owns 51,760 shares in the company, valued at approximately $414,080. This trade represents a 9.45 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.00% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on NVAX. HC Wainwright reissued a “buy” rating and set a $19.00 target price on shares of Novavax in a research note on Tuesday, December 10th. BTIG Research initiated coverage on Novavax in a report on Friday, February 28th. They set a “buy” rating and a $19.00 price target for the company. Finally, TD Cowen raised Novavax to a “hold” rating in a report on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $18.00.

Novavax Price Performance

NASDAQ:NVAX opened at $7.60 on Friday. The business has a 50 day moving average of $8.25 and a 200 day moving average of $9.53. The company has a market capitalization of $1.22 billion, a price-to-earnings ratio of -3.36, a PEG ratio of 2.85 and a beta of 2.92. Novavax, Inc. has a 1-year low of $3.81 and a 1-year high of $23.86.

Novavax (NASDAQ:NVAX) last released its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.24. The firm had revenue of $88.31 million for the quarter, compared to the consensus estimate of $85.48 million. During the same quarter in the prior year, the firm earned ($1.44) earnings per share. As a group, sell-side analysts anticipate that Novavax, Inc. will post -1.46 EPS for the current year.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.